Zhiyi Liu | Embodied Intelligence | Best Researcher Award

Posted on by ScienceFather

Dr. Zhiyi Liu | Embodied Intelligence | Best Researcher Award

Chief Scientist at Eastmoney AI Research Institute, China

The individual is a distinguished AI scientist with a vast background in multimodal AI, data integration, and financial technology. 📊 They have contributed significantly to AI applications across various industries, including search engines, digital healthcare, and financial markets. 🌐 Holding senior positions at prominent companies such as Baidu, SenseTime, and East Money Group, they have driven innovation in AI algorithms and system architecture. 💻 Their leadership in AI governance and multimodal model development has solidified their role as a key player in the AI landscape. 🤖 Additionally, their collaboration with academic and industry leaders, including Professor Andrew Ng, has furthered the integration of cutting-edge AI into real-world applications.

Publication Profile

scholar

Education 🎓

They are pursuing an IMBA at the University of Hong Kong Business School (2024-2026).  They completed their Doctorate in Intelligent Manufacturing at ISTEC Paris (2021-2024).  Their undergraduate education is in Computer Science and Technology from Beijing University of Posts and Telecommunications (2007-2011).  Throughout their academic career, they have focused on merging technical expertise with strategic innovation, especially in fields related to AI, intelligent manufacturing, and business. Their education has laid a solid foundation for their work, combining both advanced technical skills and a keen understanding of the business implications of AI technologies.

Experience 🔧

Currently, they are the Principal Scientist & Executive Dean at East Money Group, leading intelligent financial risk assessment models.  Prior to this, they co-founded and served as an AI scientist at SenseTime (2019-2022), where they led multimodal data fusion projects.  At Baidu (2011-2018), they spearheaded the integration of AI into search technologies and collaborated with top AI experts, including Andrew Ng. 🤝 They have also contributed to the development of multimodal AI models at the Chinese Academy of Sciences (2018-2019). Their diverse experience encompasses AI applications in finance, healthcare, and autonomous systems.

Awards and Honors 🏆 

At the international level, they are a member of the technical committee for the IEEE CCAI 2024 conference and a technical expert for the IEC/SMB/SEG12 Bio-digital Convergence System Evaluation Team.  Nationally, they are a member of the AI Ethics Working Committee of the Chinese Association for Artificial Intelligence and an expert on Chinese AI standards. 🇨🇳 They are a distinguished fellow at Shanghai Jiaotong University’s AI and Marketing Research Center and serve as the Executive Director of the Research Center for Computational Law and AI Ethics. 🏅 Their accolades reflect their contributions to AI ethics, governance, and research.

Research Focus  🔬

Their research centers on multimodal AI, integrating data streams from text, images, speech, and video to enhance AI’s cognitive abilities. 🧠 They have made significant advancements in natural language processing (NLP), computer vision, and deep learning.  Their work also addresses AI governance, ensuring transparency, fairness, and compliance in AI systems.  They focus on practical applications in digital healthcare, where multimodal data fusion has improved diagnostic accuracy and patient care.  Additionally, they have applied AI innovations to financial markets, optimizing decision-making through advanced algorithms and risk assessment models.

Conclusion

This candidate demonstrates exceptional qualifications for the Best Researcher Award, thanks to their pioneering work in embodied intelligence, multimodal AI models, and cross-sector applications. Their leadership in AI innovation, coupled with their significant academic influence and contributions to AI ethics, makes them a standout nominee. By leveraging further commercial application and broadening international collaborations, they can continue to push the boundaries of AI research, solidifying their position as a leading researcher in the global AI community.

Publication  Top Notes

Development Paradigm of Artificial Intelligence in China from the Perspective of Digital Economics 📊: Z Liu, Y Zheng explore the AI development in China’s digital economy. (Journal of Chinese Economic and Business Studies, 2022)

Evolving Financial Markets: The Impact and Efficiency of AI-Driven Trading Strategies 💹: Z Liu, K Zhang, D Miao discuss the role of AI in enhancing trading efficiency. (International Conference on Intelligence Science, 2024)

Research on Intelligent Computing and Trustworthy Machine Learning in Financial Complex Systems 🤖: Z Liu, K Zhang, Y Zheng, S Xu, J Qu investigate AI applications in financial systems. (2024 International Conference on Data-Driven Optimization)

Application Methods of Large Language Model Interpretability in FinTech Scenarios 💼: Z Liu, K Zhang, Y Zheng, Z Sun study LLM interpretability in financial technology. (2024 International Conference on Computer Communication and Artificial Intelligence)

Application of Visualization Methods in Neural Network Training Processes 👁️: Z Liu, K Zhang, Y Zheng, L Zheng examine neural network training visualization techniques. (2024 International Symposium on AI)

A New Era of Financial Services: How AI Enhances Investment Efficiency 💼📈: Z Liu, K Zhang, H Zhang explore AI’s role in improving investment practices. (International Studies of Economics, 2024)

alain R THIERRY | Data Science and Deep Learning | Excellence in Research

Posted on by ScienceFather

Prof. alain R THIERRY  | Data Science and Deep Learning | Excellence in Research

Director of Research, INSERM U1194, France

Dr. alain R THIERRY, a distinguished biologist, and cancer researcher, is a Director of Research at INSERM and a key figure at the Institut de Recherche en Cancérologie de Montpellier. With an impressive track record in molecular biology, gene therapy, and cancer research, Dr. alain R THIERRY has held numerous influential positions in academia and the biotechnology sector, including roles at NIH and Georgetown University. A prolific author and scientific leader, they have also founded biotech companies like MedinCell and DiaDx. Dr. alain R THIERRYcontinues to drive innovative therapeutic solutions, recognized by international honors and awards.

Publication Profile

scholar

Education🎓 

2003: Habilitation à Diriger les Recherches (HDR) in Biology-Health, Université Montpellier II 1987: CES in Human Biology (Oncology), Faculté de Médecine Paris-Sud 1986: PhD in Biochemistry, Cellular & Molecular Pharmacology, Université Montpellier II 1983: MSc in Cellular & Molecular Biology, Université de Clermont-Ferrand II 1983: Diplôme d’Ingénieur, Université Clermont-Fd II 1982: BSc in Biological Sciences & Technology, Université Clermont-Fd

Professional Experience💼 

208-present: Director of Research, INSERM, Institut de Recherche en Cancérologie, Montpellier 2001-2007: Associate Professor, Université Montpellier II2003-2004: Director of R&D, MedinCell SA, Montpellier 1997-2000: Scientific Director, Gene Therapy Dept., Biovector Therapeutics 1992-1996: Scientist, Tumor Cell Biology Lab, NCI/NIH, Bethesda 1992-1994: Adjunct Assistant Professor, Lombardi Cancer Institute, Washington DC 1988-1992: Postdoctoral Fellow, Lombardi Cancer Center, Georgetown University

Awards and Honors🏆 

1994: Federal Technology Award, NIH, USA ($10,000) 2002: Prix National de l’Innovation, Ministry of Education and Research, Paris (€300,000) 2016: Grand Prix de l’Innovation Thérapeutique, Fondation B. Denys & FRM, Montpellier (€50,000) 2022: Finalist, Prix Innovation Unicancer 2022: Innovation Award, Montpellier Université Excellence

Research Focus 🔬 

Molecular Oncology: Pioneer in understanding the molecular pathways of cancer and therapeutic gene delivery Gene Therapy: Focus on targeted gene therapy to treat cancers, with expertise in vectors and delivery systems Circulating DNA: Breakthrough research in non-invasive biomarkers for early cancer detection
Therapeutics Innovation: Key developer of novel therapeutic strategies, including drug delivery systems and cancer diagnostics
Collaborative Research: Strong interdisciplinary collaborations in biotechnology and cancer research

Publication  Top Notes

  • Origins, structures, and functions of circulating DNA in oncology
    AR Thierry, S El Messaoudi, PB Gahan, P Anker, M Stroun
    Cancer and Metastasis Reviews, 2016 | 812 citations
  • Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
    AR Thierry, F Mouliere, S El Messaoudi, C Mollevi, E Lopez-Crapez
    Nature Medicine, 2014 | 735 citations
  • Nomenclature for synthetic gene delivery systems
    PL Felgner, Y Barenholz, JP Behr, SH Cheng, P Cullis, L Huang, AR Thierry
    Human Gene Therapy, 1997 | 652 citations
  • High fragmentation characterizes tumour-derived circulating DNA
    F Mouliere, B Robert, E Arnau Peyrotte, M Del Rio, M Ychou, F Molina, AR Thierry
    PLOS One, 2011 | 627 citations
  • Circulating cell-free DNA: preanalytical considerations
    S El Messaoudi, F Rolet, F Mouliere, AR Thierry
    Clinica Chimica Acta, 2013 | 602 citations

Conclusion:

This individual is highly suitable for the Best Researcher Award. Their long-standing career in oncology research, leadership in both academic and biotech sectors, and recognition through awards place them in an elite category of researchers. Continued engagement in broader interdisciplinary fields and public communication could further elevate their profile. Overall, their qualifications, contributions, and leadership make them a strong candidate for excellence in research awards.